Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The uniQure N.V. (QURE) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, uniQure files current reports on Form 8‑K, annual reports on Form 10‑K, and quarterly reports on Form 10‑Q that describe its gene therapy business, clinical programs, financial condition, and material agreements. These filings document the company’s work in hemophilia B, Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe conditions.
For uniQure, Form 8‑K filings are particularly important. They include clinical and regulatory updates on AMT‑130 for Huntington’s disease, such as topline Phase I/II data, details of pivotal trial design, and feedback from pre‑Biologics License Application meetings with the U.S. Food and Drug Administration. Other 8‑K reports describe public offerings of ordinary shares and pre‑funded warrants, amendments to senior secured term loan facilities with Hercules Capital, and the establishment of at‑the‑market equity programs. Filings also reference the company’s role in the multi‑year clinical development of a gene therapy for hemophilia B and its licensing arrangements with CSL.
On this page, investors can review uniQure’s SEC documents to understand how it reports results of operations, research and development spending, direct financial obligations, and other events that may affect QURE stock. Stock Titan enhances access to these filings with AI‑powered summaries that highlight key points from lengthy reports, helping readers quickly identify major clinical milestones, regulatory decisions, financing terms, and risk disclosures. Real‑time updates from EDGAR, along with structured access to items such as 8‑K current reports and other registered offerings, support deeper analysis of uniQure’s evolving gene therapy portfolio and capital structure.
uniQure Director David D. Meek reported a non-discretionary sale of 2,112 ordinary shares on June 20, 2025, at a weighted average price of $14.45 per share (range: $14.40-$14.50). The transaction was executed to cover estimated withholding taxes following the vesting of restricted share units, in accordance with automatic sale instructions in the Restricted Share Unit Agreement.
Following the reported transaction, Meek continues to directly own 34,190 ordinary shares of uniQure. The sale was conducted through automatic sale instructions and was not a discretionary trade by the reporting person.
- Transaction Type: Non-discretionary sale (tax withholding)
- Transaction Code: S
- Ownership Type: Direct
- Role: Director
uniQure N.V. Chief Legal Officer Jeannette Potts reported a non-discretionary sale of 4,670 ordinary shares on June 16, 2025, at a weighted average price of $15.14 per share (range: $15.00-$15.22).
Key details of the transaction:
- The sale was automatically executed to cover estimated tax withholding obligations upon the vesting of restricted share units
- Transaction was made pursuant to automatic sale instructions in the Restricted Share Unit Agreement
- Following the transaction, Potts directly owns 115,073 ordinary shares
- The sale was non-discretionary and not a voluntary trade by the insider
This Form 4 filing was signed by Christian Klemt as Attorney-in-Fact on June 20, 2025, and demonstrates standard tax-related share disposition following equity compensation vesting.